Literature DB >> 8157021

Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency.

B Chabrol1, J Mancini, D Chretien, P Rustin, A Munnich, N Pinsard.   

Abstract

We report a 3 year-old girl with a myoclonic epilepsy. A fatal hepatic failure occurred after 3 months of valproate (VPA) therapy. In this patient, a defect of cytochrome c oxidase (COX) was demonstrated in her circulating lymphocytes. The enzyme was also found to be deficient in post-mortem liver and in cultured skin fibroblasts. However, a fully functional respiratory chain was found in muscle. VPA administration apparently triggered the hepatic failure, given this patient's background of partial COX deficiency.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157021     DOI: 10.1007/bf01959226

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy.

Authors:  A Rötig; V Cormier; S Blanche; J P Bonnefont; F Ledeist; N Romero; J Schmitz; P Rustin; A Fischer; J M Saudubray
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 2.  Valproate toxicity: risk-screening strategies.

Authors:  L J Willmore; W J Triggs; J M Pellock
Journal:  J Child Neurol       Date:  1991-01       Impact factor: 1.987

3.  Hepatic failure in disorders of oxidative phosphorylation with neonatal onset.

Authors:  V Cormier; P Rustin; J P Bonnefont; C Rambaud; A Vassault; D Rabier; P Parvy; S Couderc; F Parrot-Roulaud; M Carré
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

4.  Fatal neonatal hepatocellular deficiency with lactic acidosis: a defect of the respiratory chain.

Authors:  F Parrot-Roulaud; M Carre; T Lamirau; T Letellier; M Malgat; J P Mazat; A Munnich; J L Demarquez
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 5.  Valproate toxicity.

Authors:  J K Brown
Journal:  Dev Med Child Neurol       Date:  1988-02       Impact factor: 5.449

Review 6.  Carnitine, valproate, and toxicity.

Authors:  D L Coulter
Journal:  J Child Neurol       Date:  1991-01       Impact factor: 1.987

7.  Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.

Authors:  A E Rettie; A W Rettenmeier; W N Howald; T A Baillie
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

8.  Clinical aspects of mitochondrial disorders.

Authors:  A Munnich; P Rustin; A Rötig; D Chretien; J P Bonnefont; C Nuttin; V Cormier; A Vassault; P Parvy; J Bardet
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

9.  Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.

Authors:  T Kondo; S Kaneko; K Otani; M Ishida; T Hirano; Y Fukushima; H Muranaka; N Koide; M Yokoyama
Journal:  Epilepsia       Date:  1992 Jan-Feb       Impact factor: 5.864

10.  Valproic acid hepatic fatalities. II. US experience since 1984.

Authors:  F E Dreifuss; D H Langer; K A Moline; J E Maxwell
Journal:  Neurology       Date:  1989-02       Impact factor: 9.910

View more
  12 in total

1.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

2.  Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA.

Authors:  Chih-Ming Lin; Peterus Thajeb
Journal:  Metab Brain Dis       Date:  2007-01-17       Impact factor: 3.584

Review 3.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Clinical presentations and laboratory investigations in respiratory chain deficiency.

Authors:  A Munnich; A Rötig; D Chretien; J M Saudubray; V Cormier; P Rustin
Journal:  Eur J Pediatr       Date:  1996-04       Impact factor: 3.183

Review 5.  Clinical presentation of mitochondrial disorders in childhood.

Authors:  A Munnich; A Rötig; D Chretien; V Cormier; T Bourgeron; J P Bonnefont; J M Saudubray; P Rustin
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

6.  Valproate and cytochrome c oxidase deficiency.

Authors:  S Ponchaut; F Van Hoof; K Veitch
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

Review 7.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

Review 8.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

Review 9.  Mitochondrial cytochrome c oxidase deficiency.

Authors:  Malgorzata Rak; Paule Bénit; Dominique Chrétien; Juliette Bouchereau; Manuel Schiff; Riyad El-Khoury; Alexander Tzagoloff; Pierre Rustin
Journal:  Clin Sci (Lond)       Date:  2016-03       Impact factor: 6.124

10.  Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders due to polymerase gamma (POLG1) mutations.

Authors:  Maaike C de Vries; Richard J Rodenburg; Eva Morava; Edwin P M van Kaauwen; Henk ter Laak; Reinier A Mullaart; Irina N Snoeck; Peter M van Hasselt; Peter Harding; Lambert P W van den Heuvel; Jan A M Smeitink
Journal:  Eur J Pediatr       Date:  2006-09-07       Impact factor: 3.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.